MedTrace Logo

Antithrombin III Concentrate After Liver Transplantation

NCT04219579 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2022-07-01

No results posted yet for this study

Summary

This study was designed to demonstrate more effective administration method of AT-III in immediate post-liver transplantation period.

Conditions

  • Liver Transplant; Complications

Interventions

DRUG

Antithrombin III, continuous infusion

Antithrombin-III is administered continuously

DRUG

Antithrombin III, Intermittent infusion

Antithrombin-III is administered intermittently

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Ho Geol Ryu, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-03
Primary Completion
2022-06-28
Completion
2022-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04219579 on ClinicalTrials.gov